1.
Of the five sesquiterpene antibiotics tested and found to inhibit protein synthesis in yeast spheroplasts, trichothecin, trichodermol or trichodermin stabilized polyribosomes whereas, in contrast, verrucarin A or T-2 toxin induced 'run off' of polyribosomes with a corresponding increase in 80S monoribosomes. The effect of fusarenon X on the system could not be determined as the drug failed to enter the cells. 2. [acetyl-'4C] Trichodermin bound to yeast polyribosomes with a dissociation constant of 2.10,uM and to yeast 'run off' ribosomes with a dissociation constant of 0.721uM. 3. Trichothecin, trichodermol, fusarenon X, T-2 toxin and verrucarin A competed with [acetyl-14C] trichodermin for binding to its receptor site on 'run off' ribosomes. The observed competition was quantitatively similar for all the drugs testetl. In contrast, the five drugs competed to different extents with trichodermin for binding to its receptor site on polyribosomes. Thus trichothecin competed with relative efficiency, whereas verrucarin A competed poorly, and the other drugs occupied intermediate positions between these two extremes. 4. Studies were also carried out with yeast 'run off' ribosomes prepared from both a wild-type strain and a strain resistant to trichodermin. Competition experiments between verrucarin A and PH]anisomycin indicated that verrucarin A bound to 'run off' ribosomes from the mutant strain less efficiently than to those from the wild-type.
The sesquiterpene antibiotics trichothecin, trichodermol, trichodermin, fusarenon X, verrucarin A and T-2 toxin are effective inhibitors of eukaryotic protein synthesis assayed under a variety of experimental conditions (Ueno, 1970; Bamburg & Strong, 1971; Ohtsubo et al., 1972; Cundliffe et al., 1974) . Although these compounds can inhibit the activity of the peptidyl transferase centre on eukaryotic ribosomes as assayed by the 'fragment reaction' (Carrasco et al., 1973) , the drugs behave very differently when added to systems such as yeast spheroplasts synthesizing protein or to HeLa cells growing in culture (Cundliffe et a!., 1974) . In these systems trichodermin, for example, stabilizes polyribosome profiles, whereas, in contrast, verrucarin A induces extensive 'run off' of polyribosomes. It has also been claimed that fusarenon X induces complete or partial 'run off' of polyribosomes in HeLa cells (Ohtsubo et al., 1972) or whole reticulocytes (Ueno et al., 1973) respectively and the possibility is therefore raised that verrucarin A and fusarenon X can only inhibit protein synthesis on eukaryotic ribosomes at early stages of mRNA translation.
Vol. 160 Several studies have been carried out involving quantitative binding of radioactively labelled antibiotics to ribosomes from Escherichia coli (Mao & Putterman, 1969; Fernandez-Mufnoz & Vazquez, 1973; Contreras et a., 1974) and similar methods have been applied successfully to eukaryotic ribosomes (Barbacid & Vazquez, 1974a . Such binding studies have provided information on the location of ribosomal target sites for several antibiotics and have given useful knowledge about ribosomal structure. Considerable attention has been focused on antibiotics acting on the ribosomal peptidyl transferase catalytic centre. Antibiotics in this group include gougerotin, which associates with the centre on both prokaryotic and eukaryotic ribosomes, and the two drugs anisomycin and trichodermin, which associate with the centre specifically on eukaryotic ribosomes.
In the present work we have attempted to ascertain why the various drugs in the sesquiterpene group can affect polyribosome profiles differently when added to systems synthesizing protein despite the fact that the compounds studied here have all been shown to inhibit the peptidyl transferase catalytic centre of eikaryotic ribosomes under sdected conditions in vitro (Carrasco et al., 1973) . We have bound [acetyl-14C] (wild-type) and strain TR1 (trichodermin-resistant mnutant derived from strain Y166) were grown and converted into spheroplasts (Cannon et al., 1973) . Analysis of polyribosomes from spheroplasts before and after exposure to the various sesquiterpene antibiotics tested was carried out exactly as described previously (Cannon et a., 1973) . The drugs were present for 2min each at a final concentration of 0.1 mm before analysis of polyribosomes.
Preparation of yeast polyribosomes and 'run off' ribosomes for binding studies Polyribosonies from S. cerevisiae were obtained from apheroplasts inhibited by cycloheximide (Malg/ ml) exactly as described by . 'Run off' ribosomes were prepared fromn proteinsynthesizing spheroplasts that had been treated with ImM-NaN3 for 5min Preparation ofhigh-salt-washed ribosomes Ribosomes from S. cerevisiae were prepared and then washed extensively in high-salt solution as described by Battaner & Vazquez (1971 Conditions for preparation of yeast spheroplasts are described in the Experimental section. Samples (lOml) were incubated at 30°C for 2mi in the absence or presencee of 0.1 mm-trichothecin or 0.1 nm-verrucarin A. Protein synthesis was stopped by the addition of cycloheximide (l1O0pg/ml) to 'freeze' polyribosomes. Spheroplasts were then treated and analysed for their polyribosome content as described by Cannon et al. (1973) . (a) Control lysate; (b) effect of trichothecin; (c) effect of verrucarin A. For binding studies, polyribosomes and 'run off' ribosomes were prepared and analysed on sucrose gradients as described by Cannon et al. (1973 Cannon, unpublished work). We were unable to check the effect of fusarenon X on the spheroplast system, since the drug fails to enter the cells . However, it has been reported that fusarenon X induced 'run off' of polyribosomes in both HeLa cells and whole reticulocytes (Ohtsubo et al., 1972; Ueno et al., 1973) , although in the latter system the 'run off' effect was incomplete. [acetyl-14C] trichodermin to polyribosomes and 'run off' ribosomes (and where specified to ribonucleasedegraded polyribosomes) was carried out as described in the Experimental section in the presence or the absence of verrucarin A, T-2 toxin, fusarenon X or trichothecin at the concentrations indicated. Reaction mixtures containing verrucarin A or T-2 toxin had a final volume of 100pl, and 301ul samples were removed before and after centrifugation for determination of radioactivity. Those reaction mixtures containing fusarenon X and trichothecin had a final volume of 80j1l and the samples removed for determination ofradioactivity had a volume of20,p1. In all reaction mixtures containing verrucarin A or T-2 toxin dimethyl sulphoxide (2%, v/v) was present. Similarly, ethanol was present at final concentrations (v/v) of 2% or 5% in all the reaction mixtures containing fusarenon X or trichothecin respectively. e, Binding to polyribosomes; *, ribonuclease-treated polyribosomes; o, 'run off' ribosomes. (Fig. 3a) . The same graph indicates that, in complete contrast with this result, verrucarin A at a concentration of 4.5 fM inhibited binding of [acetyl-'4C] trichodermin to 'run off' ribosomes by 55% and at a concentration of 100AM by 84%. We also carried out identical competition experiments using a preparation of polyribosomes that had been completely degraded to monoribosomes by incubation with pancreatic ribonuclease (absorbance profile not shown) and again the results are illustrated in Fig. 3(a) . The data were essentially identical with those obtained when [acetyl-14C] trichodermin was bound to polyribosomes, and again verrucarin A failed to inhibit significantly the binding of the drug, except when verrucarin A was present at very high concentrations. This last result indicates that the physical presence of the polyribosome aggregate is not in itself responsible for the lack of competition between verrucarin A and trichodermin, and suggests that the exclusion of verrucarin A is a property of each individual monoribosome engaged in protein synthesis.
We then repeated the same binding experiments with polyribosomes and 'run off' ribosomes using [acetyl-14C] trichodermin in the presence of either fusarenon X or T-2 toxin; our results with fusarenon X are shown in Fig. 3(b) . Fusarenon X competed Vol. 160 with trichodermin for binding to 'run off' ribosomes in a quantitatively similar way to that observed for verrucarin A. However, in addition fusarenon X competed with trichodermin, more efficiently than had verrucarin A, for binding to polyribosomes. Thus fusarenon X at a concentration tenfold in excess of that of trichodermin competed with the latter by 40%. This value is to be compared with that for verrucarin A (10 %) added at the same relative concentration (see Fig. 3a ). Our results for the corresponding experiments using T-2 toxin are in Fig. 3(c) . Binding experiments using 'run off' ribosomes gave results almost identical with those obtained for the other two drugs (fusarenon X and verrucarin A), and the data obtained by using polyribosomes were very similar to those obtained with verrucarin A, although T-2 toxin had a slightly higher affinity for such preparations.
With equimolar amounts of [acetyl-'4C]trichodermin and trichodermin, the binding of the former is predictably decreased to approx. 50% relative to controls containing only [acetyl-14C]trichodermin, and this effect, as expected, is identical when either polyribosomes or 'run off' ribosomes are used (results not shown). From the above results it is clear that fusarenon X, verrucarin A and T-2 toxin can compete fully with trichodermin for its binding site only when 'run off' ribosomes are used. We turned our attention therefore to the drug trichothecin, which, as we have shown, stabilized polyribosome profiles in a manner characteristic also of trichodermin. This similarity indicates that both drugs can gain access to their target sites on polyribosomes and we should predict that the drugs might compete for this same receptor site(s) on isolated polyribosomes. We therefore carried out competition experiments with both polyribosomes and 'run off' ribosomes (Fig. 3d) (1974) , trichothecin and trichodermol would qualify as E-type inhibitors, whereas T-toxin and fusarenon X would qualify as I-type inhibitors. A somewhat different interpretation for the mode of action of the 1-type inhibitor T-2 toxin has been invoked (Smith et al., 1975; Cannon et al., 1976) , and this interpretation is supported by the work reported here. Although Smith et al. (1975) reported that T-2 toxin was capable of inhibiting polypeptide-chain initiation by preventing the formation of the first peptide bond in the protein-synthesizing cycle, this reaction is not uniquely susceptible. Thus Cannon et al. (1976) have claimed that T-2 toxin can inhibit early peptide-bond-forming steps during poly(U)-directed polyphenylalanine synthesis in reticulocyte lysates, but that nascent polyphenylalanine chains above a certain critical chain length (and bound to ribosomes through tRNA) exclude the drug from functional interaction with its target site. Our present work with both T-2 toxin and verrucarin A shows that these inhibitors also fail to associate with their ribosomal receptor site(s), presumably the peptidyl transferase catalytic centre, under certain conditions. Thus both drugs bind to polyribosomes rather inefficiently, but nevertheless associate in specific fashion with 'run off' ribosomes. One obvious difference between these ribosome types is the absence of nascent peptides on the 'run off' ribosomes. From these considerations it is clear that division of the sesquiterpene drugs into I types and E types is arbitrary, since both T-2 toxin and verrucarin A can now be thought of as inhibitors of peptide-chain elongation (E-type inhibitors) under conditions where the chain length of the ribosomebound nascent peptide still allows the drugs to react with their ribosomal target site(s).
We must now consider in more detail the binding of [acetyl-i4C] trichodermin to polyribosomes and 'run off' ribosomes. Barbacid & Vazquez (1974a) have shown that trichodermin binds to the peptidyl transferase centre and that this binding is inhibited by anisomycin, a known inhibitor of peptidyl transferase reactions on eukaryotic ribosomes (Grollman, 1967 (Carrasco et al., 1973) .
Further, the drugs inhibit, albeit partially, the binding of CACCA-Leu-Ac to the donor site and of UACCA-Leu to the acceptor site of the yeast ribosomal peptidyl transferase catalytic centre, the latter reaction being inhibited preferentially. These observations support the idea that all the drugs have the peptidyl transferase centre as their target site, but it is noteworthy that both assays, the fragment Vol. 160 reaction and substrate binding, use ribosonies that are devoid of peptidyl-tRNA. Ohtsubo et al. (1972) found that fusarenon X induced polyribosome 'run off' in HeLa cells and subsequently Ueno et at. (1973) showed that the same drug (added at a concentration of 24uM) induced partial 'run off' of polyribosomes in whole reticulocytes. Thus fusarenon X would have been classified, along with verrucarin A and T-2 toxin, as an I-type inhibitor (Cundliffe et al., 1974) . However, although verrucarin A, T-2 toxin and fusarenon X all inhibit the fragmnent reaction (Carrasco et at., 1973) , fusarenon X alone of these three drugs is an effective inhibitor of both polypeptide synthesis and peptidyl-puromycin formation as catalysed by yeast polyribosomes, and this behaviour would not be expected from a drug that induces 'run off' of polyribosomes. This apparent paradox can now be explained by the results we have presented in this paper. The ability of a given sesquiterpene antibiotic to inhibit any function on polyribosomes depends critically on the affinity of that drug for its receptor site. Fusarenon X has a high enough affinity for polyribosomes to inhibit function(s) associated with these complexes, in contrast with both T-2 toxin and verrucarin A where affinity for polyribosomes is too low for any inhibition to be apparent. We emphasize, however, that the affinity of fusarenon X for polyribosomes is such that effective interaction is concentration-dependent and in the experiments of Ohtsubo et at. (1972) and Ueno et at. (1973) higher drug concentrations would perhaps have stabilized polyribosome profiles, although we stress that this is not the case for either verrucarin A or T-2 toxin (Cundliffe et al., 1974) .
Similar considerations could also explain why trichodermin is more active than trichothecin in inhibiting peptidyl-puromycin formnation as catalysd by yeast polyribosomes and why all the drugs studied here inhibit the fragment reaction where polyribosomes are not used (Carrasco et al., 1973) . It has already been suggested by that trichodermin, trichothecin and fusarenon X have a common binding site on 60S ribosomal subunits, which overlaps with or is closely linked to the binding site of anisomycin, and the results we have presented do not disagree with such an interpretation. Further, fusarenon X, trichodermin and trichothecin show a decrease in their binding efficiency to ribosomes from a yeast mutant resistant to trichodermin (Barbacid & Vazquez, 1974a,b) . Further, verrucarin A bound with equal affinity to high-salt-washed . These results suggested strongly that verrucarin A had a different ribosomal receptor site from that for trichodermin and trichothecin (see also Schindler, 1974) . It now appears, however, that ribosomes washed in high-salt solution contain a great deal of bound peptidyl-tRNA, in contrast with 'run off' ribosomes, which, as expected, do not (L. Carrasco & A. Jimenez, personal communication) . Thus verrucarin A failed to produce an effect earlier (Barbacid & Vazquez, 1974a,b) ; this mutant is also resistant to anisomycin. However, although trichodermin and anisomycin bind to mutually exclusive sites, the ribosomal mutation leading to both trichodermin resistance and anisomycin resistance decreases the binding affinity for trichodermin alone. For anisomycin, therefore, resistance does not result from a decreased binding affinity, but may be explained on the basis of a conformational and/or structural change at the peptidyl transferase catalytic centre, which allows anisomycin to bind but lowers the ability of the drug to inhibit peptide-bond formation. We prepared 'run off' ribosomes from both the parent yeast (strain Y166) and the mutant resistant to trichodermin (strain TR1) and studied the ability of verrucarin A to compete with [3H]anisomycin for binding to both ribosome preparations. The results are shown in Table 1 . Clearly, 'run off' ribosomes from the trichodermin-resistant mutant bind verrucarin A with much less efficiency than do 'run off' ribosomes obtained from the yeast parent strain. This result is similar to those reported by showing competition, between trichodermin, trichothecin and fusarenon X, for binding of [3H] anisomycin to high-salt-washed ribosomes from both strains of yeast Y166 and TR,.
Our results indicate clearly that verrucarin A can now be included with trichothecin and fusarenon X in that all three drugs share with trichodermin a common, or at least overlapping, binding site on yeast ribosomes (see also Schindler, 1974) . The suggestion by that verrucarin A has a different ribosomal receptor site from the other three sesquiterpene drugs studied is apparently incorrect, since their results were obtained with ribosomes that were carrying nascent polypeptidyl-tRNA chains.
In the present work we have shown that at least four of the sesquiterpene antibiotics (trichodermin, trichothecin, fusarenon X and verrucarin A) share, at least in part, a common receptor site on eukaryotic ribosomes, and we suggest that this same site is also shared by T-2 toxin and trichodermol. Barbacid & Vazquez (1974a,b) have claimed that trichodermol shows good competition with [acetyl-14C]trichodermin for its ribosomal target site. We have suggested that the drugs can be impeded from interaction with the same (presumably) receptor site on polyribosomes by the presence of peptidyl-tRNA and that the degree of exclusion depends on the structure of each individual antibiotic. It would be instructive to extend our methodology towards other compounds within the sesquiterpene group with the intention of deciding whether or not all such compounds have the peptidyl transferase catalytic centre as their sole ribosomal receptor site. 
